United Therapeutics (UTHR) announced that it will enter into two accelerated share repurchase agreements with Citibank to repurchase an aggregate $1B of common stock. United Therapeutics will repurchase these shares under the $1B repurchase program authorized by the company’s board of directors and previously announced on July 30.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics Reports Record Revenue and Growth
- Hold Rating for United Therapeutics Amid Mixed Tyvaso Performance and Competitive Challenges
- United Therapeutics: Hold Rating Amid Uncertain Competitive Pressures and Awaiting Key Data
- Optimistic Buy Rating for United Therapeutics Driven by Promising TETON Trial Prospects for Tyvaso in IPF Market
- United Therapeutics price target lowered to $400 from $425 at H.C. Wainwright